Results from a trial of a new Ebola vaccine confirm it can progress to larger scale testing. The results from the first clinical trials of the proposed new vaccine in the UK show that it does produce a response from the immune system. Trials in affected countries are now needed to see whether it is sufficient to protect against the disease. The research will also help determine the appropriate dosage for patients.
The vaccine has been developed by British pharmaceutical company GlaxoSmithKline and the US National Institutes of Health. The UK-based trials were carried out by Oxford University’s Jenner Institute with funding from the UK Government, the Wellcome Trust and the Medical Research Council.
